Parenteral supplementation with EPA/DHA omega-3 fatty acids improves recovery prognosis in critically ill patients
Nutrición Hospitalaria · 2022
DOI: 10.20960/nh.04227 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrición Hospitalaria, 2022. Verfasst von Ethel Lira Marcial und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Nutrición Clínica Parenteral. Hospital General de Puebla "Dr. Eduardo Vázquez Navarro". Facultad de Medicina, Licenciatura en Nutrición C…. Hauptthemen laut MEDLINE: Critical Illness, Fatty Acids, Omega-3. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Introduction: the decision to supplement total parenteral nutrition (TPN) with emulsions of omega-3 (Ω3) eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids (FA) of marine origin is based on the clinical benefits obtained in different medical situations and surgical procedures, among which reductions in hospital stay, days of mechanical ventilation, incidence of infections and mortality stand out. However, the evidence in critically ill patients remains contradictory. Objective: the objective of this clinical trial was to analyze the effect of supplementation with EPA/DHA Ω3 FAs on clinical prognostic markers -medical, nutritional and biochemical- in critically ill patients, relating to outcome. Method: a clinical, controlled, randomized, single-center trial in 64 critically ill adult patients, of which 47 patients were randomized to receive TPN supplemented with EPA/DHA Ω3 FAs in doses of 0.1 g/kg/day (n = 23) and 0.2 g/kg/day (n = 24), compared with a historical control group with TPN without supplementation (n = 17). Clinical prognosis markers were determined at baseline and at the end of nutritional support (medical, nutritional and biochemical). Results: the two groups with supplementation showed a statistically significant reduction in mortality (p < 0.005); the clinical prognostic markers SOFA, APACHE II, SAPS 3, NUTRIC, RTL and CRS were consistent in showing a significant improvement (p < 0.005), of prognosis with doses of 0.1 and 0.2 g/kg/day of EPA/DHA Ω3 FAs, respectively. Conclusion: supplementation of parenteral nutrition with EPA/DHA Ω3 fatty acids at doses of 0.1 g and 0.2 g/kg/day improves recovery prognosis and the probability of survival in critically ill patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Nutrición Clínica Parenteral. Hospital General de Puebla "Dr. Eduardo Vázquez Navarro". Facultad de Medicina, Licenciatura en Nutrición Clínica. Benemérita Universidad Autónoma de Puebla.
- División de Estudios de Posgrado e Investigación.Tecnológico Nacional de México/Instituto Tecnológico de Oaxaca.
- Servicio de Nutrición Clínica Parenteral. Hospital General de Puebla "Dr. Eduardo Vázquez Navarro".
Zitieren
APA
Lira Marcial, E., García-Montalvo, I. A., Contreras Oliveros, M. L. Á., & Macías Moreno, M. (2022). Parenteral supplementation with EPA/DHA omega-3 fatty acids improves recovery prognosis in critically ill patients. Nutrición Hospitalaria. https://doi.org/10.20960/nh.04227
Vancouver
Lira Marcial E, García-Montalvo IA, Contreras Oliveros MLÁ, Macías Moreno M. Parenteral supplementation with EPA/DHA omega-3 fatty acids improves recovery prognosis in critically ill patients. Nutrición Hospitalaria. 2022. doi:10.20960/nh.04227
BibTeX
@article{LiraMarcial2022,
author = {Lira Marcial, Ethel and García-Montalvo, Iván Antonio and Contreras Oliveros, María de Los Ángeles and Macías Moreno, Michelle},
title = {Parenteral supplementation with EPA/DHA omega-3 fatty acids improves recovery prognosis in critically ill patients},
journal = {Nutrición Hospitalaria},
year = {2022},
doi = {10.20960/nh.04227}
}
EUVIMED